JPS531190B2
(es)
|
1974-02-22 |
1978-01-17 |
|
|
NL7605526A
(nl)
|
1976-05-24 |
1977-11-28 |
Akzo Nv |
Nieuwe tetracyclische derivaten.
|
US4154836A
(en)
|
1976-05-24 |
1979-05-15 |
Akzona Incorporated |
Tension reducing 1,2,3,4,4a,13b-hexahydro-dibenz[2,3;6,7]oxepino[4,5-c]pyridines
|
JPS61502751A
(ja)
*
|
1984-07-23 |
1986-11-27 |
シエリング,コ−ポレ−シヨン |
アザタジンの経度デリバリ−
|
US5474783A
(en)
|
1988-03-04 |
1995-12-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
US5446070A
(en)
|
1991-02-27 |
1995-08-29 |
Nover Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US5656286A
(en)
|
1988-03-04 |
1997-08-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
EP0387751B1
(en)
|
1989-03-15 |
1994-06-08 |
Nitto Denko Corporation |
Medicated plasters
|
DE3937271A1
(de)
|
1989-11-09 |
1991-05-16 |
Boehringer Ingelheim Kg |
Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
|
EP0569096A1
(en)
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
HU225051B1
(en)
|
1994-03-02 |
2006-05-29 |
Organon Ireland Ltd |
Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
JP3274579B2
(ja)
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
KR100213465B1
(ko)
|
1996-11-01 |
1999-08-02 |
최좌진 |
케토프로펜 패취 조성물
|
EP0984968A1
(en)
|
1997-05-26 |
2000-03-15 |
Akzo Nobel N.V. |
Salts of aromatic sulphonic acids
|
US7150881B2
(en)
|
1997-06-26 |
2006-12-19 |
Mylan Technologies, Inc. |
Adhesive mixture for transdermal delivery of highly plasticizing drugs
|
GB9714650D0
(en)
|
1997-07-11 |
1997-09-17 |
Strakan Ltd |
Block copolymer
|
WO1999032108A1
(en)
|
1997-12-19 |
1999-07-01 |
Akzo Nobel N.V. |
Org-5222 in the treatment of depression
|
DE19814083C2
(de)
|
1998-03-30 |
2002-02-07 |
Lohmann Therapie Syst Lts |
Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
|
EP1148106B1
(en)
|
1998-07-29 |
2004-11-24 |
Teijin Limited |
Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
|
US20040142024A1
(en)
|
1999-07-27 |
2004-07-22 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch formulation for external use
|
WO2001052823A2
(en)
|
2000-01-20 |
2001-07-26 |
Noven Pharmaceuticals, Inc. |
Compositions to effect the release profile in the transdermal administration of drugs
|
US7691404B2
(en)
|
2000-11-06 |
2010-04-06 |
Samyang Corporation |
Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
|
EP1353675A2
(en)
|
2001-01-02 |
2003-10-22 |
PHARMACIA & UPJOHN COMPANY |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
WO2002069942A1
(fr)
|
2001-03-07 |
2002-09-12 |
Hisamitsu Pharmaceutical Co., Inc. |
Timbre adhesif
|
CA2445528A1
(en)
|
2001-04-26 |
2002-11-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
GB0119012D0
(en)
|
2001-08-03 |
2001-09-26 |
Strakan Group Plc |
Transdermal delivery of drugs
|
JP4323138B2
(ja)
|
2002-06-05 |
2009-09-02 |
日東電工株式会社 |
経皮吸収型製剤およびその製造方法
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
US20040126323A1
(en)
*
|
2002-08-20 |
2004-07-01 |
Ihor Shevchuk |
Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent
|
AU2003268376A1
(en)
|
2002-08-30 |
2004-11-26 |
Watson Pharmaceuticals, Inc. |
Transdermal delivery systems and methods
|
AU2003284899A1
(en)
|
2002-10-29 |
2004-05-25 |
Miicro, Inc. |
Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
|
GB0302662D0
(en)
|
2003-02-05 |
2003-03-12 |
Strakan Ltd |
Transdermal granisetron
|
GB0306604D0
(en)
|
2003-03-21 |
2003-04-30 |
Curidium Ltd |
Second medical use
|
EP1633400A2
(en)
|
2003-05-16 |
2006-03-15 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
TWI327915B
(en)
|
2003-06-12 |
2010-08-01 |
Organon Nv |
Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
EP1684681B1
(en)
|
2003-10-10 |
2018-10-24 |
Oryxe |
A mixture for transdermal delivery of low and high molecular weight compounds
|
CA2542778C
(en)
|
2003-10-28 |
2012-05-29 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery composition
|
AU2004291043A1
(en)
|
2003-11-18 |
2005-06-02 |
3M Innovative Properties Company |
Olanzapine containing transdermal drug delivery compositions
|
EP1547650A1
(en)
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
PL1708790T3
(pl)
|
2003-12-02 |
2010-10-29 |
Pharmaneuroboost N V |
Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
|
EP1576985A1
(en)
|
2004-03-18 |
2005-09-21 |
B&B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
WO2005063296A2
(en)
|
2003-12-23 |
2005-07-14 |
Pfizer Products Inc. |
Therapeutic combination for cognition enhancement and psychotic disorders
|
JP2007519705A
(ja)
|
2004-01-29 |
2007-07-19 |
ファイザー・プロダクツ・インク |
Cns障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル/ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
|
CA2556160A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
US7650848B2
(en)
|
2004-02-17 |
2010-01-26 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
JP2007526328A
(ja)
|
2004-03-02 |
2007-09-13 |
ファルマシア コーポレーション |
単独および抗うつ薬と組み合わせた形のCox−2阻害剤によって精神障害を治療または予防するための方法および組成物
|
GB0405200D0
(en)
|
2004-03-08 |
2004-04-21 |
Pfizer Ltd |
Combinations comprising alpha-2-delta ligands
|
US9205062B2
(en)
|
2004-03-09 |
2015-12-08 |
Mylan Pharmaceuticals, Inc. |
Transdermal systems containing multilayer adhesive matrices to modify drug delivery
|
US20080226697A1
(en)
|
2004-04-21 |
2008-09-18 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch for External Use with Elevated Content of Absorption Promoter in Pressure-Sensitive Adhesive Base
|
NZ551340A
(en)
|
2004-04-22 |
2010-10-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
|
JP2007537232A
(ja)
|
2004-05-11 |
2007-12-20 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬と5−ht1b受容体拮抗薬の組合せ
|
WO2006000222A2
(en)
|
2004-06-24 |
2006-01-05 |
H. Lundbeck A/S |
The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
|
US20060019969A1
(en)
|
2004-07-24 |
2006-01-26 |
Laboratorios Dr. Esteve S.A. |
Use of compounds active on the sigma receptor for the treatment of allodynia
|
ITMI20041628A1
(it)
|
2004-08-06 |
2004-11-06 |
Bouty S P A |
Sistema terapeutico a rilascio controllato per uso topico transdermico
|
GB0417702D0
(en)
|
2004-08-09 |
2004-09-08 |
Merck Sharp & Dohme |
New uses
|
US20060039869A1
(en)
*
|
2004-08-17 |
2006-02-23 |
Daniel Wermeling |
Intranasal delivery of antipsychotic drugs
|
US20060078604A1
(en)
|
2004-10-08 |
2006-04-13 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery device including an occlusive backing
|
US20060078602A1
(en)
|
2004-10-08 |
2006-04-13 |
Noven Pharmaceuticals, Inc. |
Device for transdermal administration of drugs including acrylic polymers
|
MX2007004485A
(es)
|
2004-10-15 |
2007-06-13 |
Organon Nv |
Tratamiento de desordenes bipolares y sintomas asociados.
|
ATE413166T1
(de)
|
2004-11-22 |
2008-11-15 |
Hisamitsu Pharmaceutical Co |
Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
|
US20060150989A1
(en)
|
2005-01-12 |
2006-07-13 |
Peter Migaly |
Method of diagnosing, treating and educating individuals with and/or about depression
|
AU2006208630B2
(en)
|
2005-01-28 |
2011-09-29 |
Ucb Pharma Gmbh |
SPM 927 for add-on therapy of schizophrenia
|
WO2006082728A1
(ja)
|
2005-02-04 |
2006-08-10 |
Hisamitsu Pharmaceutical Co., Inc. |
経皮吸収貼付剤
|
AU2006219643A1
(en)
|
2005-03-01 |
2006-09-08 |
Pfizer Limited |
Use of PDE7 inhibitors for the treatment of neuropathic pain
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
GB0506139D0
(en)
*
|
2005-03-24 |
2005-05-04 |
Transphase Ltd |
A transdermal topical composition and its uses
|
EP1917267B1
(en)
|
2005-04-07 |
2008-12-24 |
N.V. Organon |
Crystal form of asenapine maleate
|
CN101175741B
(zh)
|
2005-04-07 |
2011-06-22 |
欧加农股份有限公司 |
用于制备反式-5-氯-2-甲基-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]-氧杂䓬并[4,5-C]吡咯的中间体化合物
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7741358B2
(en)
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
KR20080012896A
(ko)
|
2005-04-27 |
2008-02-12 |
유엠엔 파마 아이엔씨 |
췌장염 예방 및 치료제
|
EP1731143B1
(en)
|
2005-06-06 |
2008-11-26 |
Nitto Denko Corporation |
Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
|
CA2548864C
(en)
|
2005-06-06 |
2012-12-11 |
Nitto Denko Corporation |
Percutaneous absorption-type pharmaceutical preparation
|
JP5000932B2
(ja)
|
2005-06-21 |
2012-08-15 |
日東電工株式会社 |
ニコチン含有経皮吸収製剤
|
US20070015763A1
(en)
|
2005-07-12 |
2007-01-18 |
Pfizer Inc |
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
|
TW200738734A
(en)
|
2005-08-08 |
2007-10-16 |
Pfizer Prod Inc |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
|
WO2007046554A1
(ja)
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
DE102005050431A1
(de)
|
2005-10-21 |
2007-04-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
|
US7888422B2
(en)
|
2005-11-09 |
2011-02-15 |
Mylan Technologies Inc. |
Long-wearing removable pressure sensitive adhesive
|
TWI389709B
(zh)
*
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
JP5037831B2
(ja)
|
2006-02-15 |
2012-10-03 |
久光製薬株式会社 |
凝集力向上及び徐放化の外用貼付剤
|
EP2004150A1
(en)
|
2006-03-27 |
2008-12-24 |
Panacea Biotec Ltd. |
Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
|
TW200812993A
(en)
|
2006-05-02 |
2008-03-16 |
Lundbeck & Co As H |
New uses of escitalopram
|
US20070259952A1
(en)
|
2006-05-02 |
2007-11-08 |
H. Lundbeck A/S |
Uses of escitalopram
|
WO2007137224A2
(en)
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Method of treatment
|
JP5001271B2
(ja)
|
2006-06-09 |
2012-08-15 |
大日本住友製薬株式会社 |
新規テープ製剤
|
TW200817414A
(en)
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
CN101506172A
(zh)
|
2006-07-14 |
2009-08-12 |
辉瑞产品公司 |
(7S)-7-[(5-氟-2-甲基-苄基)氧基]-2-[(2R)-2-甲基哌嗪-1-基]-6,7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
CL2007002891A1
(es)
|
2006-10-06 |
2008-04-18 |
Organon Nv |
Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
|
DE102006050558B4
(de)
*
|
2006-10-26 |
2009-03-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
|
US20100048628A1
(en)
|
2006-12-01 |
2010-02-25 |
Sumiyo Nishi |
Method for suppressing discoloration over time of adhesive preparation containing donepezil
|
BRPI0719351A2
(pt)
|
2006-12-01 |
2014-01-07 |
Nitto Denko Corp |
Preparação adesiva estabilizada contendo donezepil
|
CN101563312A
(zh)
|
2006-12-22 |
2009-10-21 |
住友化学株式会社 |
阿塞那平合成中间体的制备方法
|
US7875729B2
(en)
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
WO2008089212A1
(en)
|
2007-01-16 |
2008-07-24 |
Ipintl, Llc |
Novel composition for treating metabolic syndrome
|
US20080226698A1
(en)
|
2007-03-16 |
2008-09-18 |
Mylan Technologies, Inc. |
Amorphous drug transdermal systems, manufacturing methods, and stabilization
|
FR2913882B1
(fr)
|
2007-03-20 |
2009-05-01 |
Oreal |
Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
|
WO2008141438A1
(en)
|
2007-05-17 |
2008-11-27 |
Sunnybrook Health Sciences Centre |
Gabaergic modulators for treating airway conditions
|
EP2170399A1
(en)
|
2007-06-05 |
2010-04-07 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
WO2009000890A2
(en)
|
2007-06-27 |
2008-12-31 |
N.V. Organon |
Medication container
|
JP5245428B2
(ja)
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
US20100178323A1
(en)
|
2007-07-10 |
2010-07-15 |
Agis Kydonieus |
Dermal Delivery Device
|
JP5224163B2
(ja)
|
2007-07-24 |
2013-07-03 |
コスメディ製薬株式会社 |
経皮吸収テープ製剤
|
WO2009017453A1
(en)
|
2007-07-30 |
2009-02-05 |
Astrazeneca Ab |
New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
|
WO2009017836A1
(en)
|
2007-08-01 |
2009-02-05 |
Medivation Neurology, Inc. |
Methods and compositions for treating schizophrenia using antipsychotic combination therapy
|
US20090209608A1
(en)
|
2007-08-29 |
2009-08-20 |
Protia, Llc |
Deuterium-enriched asenapine
|
JP5535914B2
(ja)
|
2007-09-10 |
2014-07-02 |
ヴァンダ ファーマシューティカルズ インコーポレイテッド |
Snp遺伝子型に基づく抗精神病薬治療
|
EP2198048A2
(en)
|
2007-09-10 |
2010-06-23 |
Vanda Pharmaceuticals Inc. |
Prediction of qt prolongation based on snp genotype
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
CA2710800A1
(en)
|
2008-01-04 |
2009-07-16 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
US8529441B2
(en)
*
|
2008-02-12 |
2013-09-10 |
Innurvation, Inc. |
Ingestible endoscopic optical scanning device
|
SG188144A1
(en)
|
2008-02-13 |
2013-03-28 |
Targacept Inc |
Alpha 7 nicotinic agonists and antipsychotics
|
JP5537412B2
(ja)
|
2008-02-27 |
2014-07-02 |
久光製薬株式会社 |
貼付製剤
|
WO2009121031A1
(en)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
JP5301190B2
(ja)
|
2008-03-31 |
2013-09-25 |
積水メディカル株式会社 |
貼付剤
|
WO2009135091A1
(en)
|
2008-04-30 |
2009-11-05 |
Medivation Technologies, Inc. |
Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
|
KR101590209B1
(ko)
|
2008-05-30 |
2016-02-01 |
밀란 인크. |
안정화 경피 약물 전달 시스템
|
WO2010011232A1
(en)
|
2008-07-24 |
2010-01-28 |
Handa Pharmaceuticals, Llc |
Stabilized atypical antipsychotic formulation
|
US9267151B2
(en)
|
2008-08-20 |
2016-02-23 |
Brainco Biopharma, S.L. |
STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
|
US9457018B2
(en)
|
2008-09-04 |
2016-10-04 |
Saniona A/S |
Method for combating adverse effects arising from antipsychotic treatment
|
WO2010060742A1
(en)
|
2008-11-03 |
2010-06-03 |
Solvay Pharmaceuticals B.V. |
Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
|
WO2010073326A1
(ja)
|
2008-12-24 |
2010-07-01 |
ニチバン株式会社 |
経皮吸収型製剤
|
WO2010080757A2
(en)
|
2009-01-07 |
2010-07-15 |
Astrazeneca Ab |
Combinations with an alpha-4beta-2 nicotinic agonist
|
EP2389187B1
(en)
|
2009-01-20 |
2016-11-16 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
|
CA2792484C
(en)
|
2009-03-12 |
2017-10-31 |
Delpor, Inc. |
Implantable device for long-term delivery of drugs
|
WO2010112529A1
(en)
|
2009-03-30 |
2010-10-07 |
Pharmaneuroboost N.V. |
Low dose pipamperone in treating mood disorders
|
AU2010226442A1
(en)
|
2009-03-20 |
2011-10-13 |
Antares Pharma, Inc. |
Hazardous agent injection system
|
WO2010110914A2
(en)
|
2009-03-27 |
2010-09-30 |
Zirus, Inc. |
Mammalian genes involved in infection
|
EP2236138A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Low dose pipamperone in treating mood and anxiety disorders
|
EP2236157A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Pipamperone and a second agent in treating mood and anxiety disorders
|
WO2010119455A2
(en)
|
2009-04-15 |
2010-10-21 |
Sun Pharma Advanced Research Company Ltd. |
An injectable sustained release pharmaceutical composition
|
JP2012524112A
(ja)
|
2009-04-21 |
2012-10-11 |
サノミューン・インコーポレイテッド |
統合失調症および双極性障害を治療するための組織カリクレイン
|
TWI471127B
(zh)
|
2009-04-29 |
2015-02-01 |
Intervet Int Bv |
供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
|
US8512742B2
(en)
|
2009-05-01 |
2013-08-20 |
Hisamitsu Pharmaceutical Co., Inc. |
Transdermal preparation
|
WO2010127674A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Sunin K/S |
Transdermal compositions of asenapine for the treatment of psychiatric disorders
|
TW201113018A
(en)
|
2009-06-24 |
2011-04-16 |
Organon Nv |
Injectable formulations containing asenapine and method of treatment using same
|
US20110306596A1
(en)
|
2009-07-27 |
2011-12-15 |
Auspex Pharmaceuticals, Inc. |
Benzazepine inhibitors of gamma-secretase
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
CN102481283A
(zh)
|
2009-08-31 |
2012-05-30 |
埃里克·B·施耐德 |
创伤或损伤后中枢神经***继发性损伤的预防和治疗
|
CA2777843A1
(en)
|
2009-10-16 |
2011-04-21 |
University Of South Florida |
Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
|
WO2011057199A1
(en)
|
2009-11-06 |
2011-05-12 |
Adenios, Inc. |
Compositions for treating cns disorders
|
RU2589697C2
(ru)
|
2009-12-18 |
2016-07-10 |
Экзодос Лайф Сайенсиз Лимитед Партнершип |
Способы получения стабильных жидких лекарственных препаратов и их композиции
|
US8202525B2
(en)
|
2009-12-22 |
2012-06-19 |
Pondera Biotechnologies, LLC |
Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
|
AR079814A1
(es)
|
2009-12-31 |
2012-02-22 |
Otsuka Pharma Co Ltd |
Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
|
WO2011084851A1
(en)
|
2010-01-07 |
2011-07-14 |
Alkermes, Inc. |
Asenapine produrugs
|
WO2011085188A1
(en)
|
2010-01-07 |
2011-07-14 |
Eurand, Inc. |
Pharmaceutical compositions comprising anti-psychotic drugs
|
JP6076740B2
(ja)
|
2010-01-07 |
2017-02-08 |
アルカーメス ファーマ アイルランド リミテッド |
第四級アンモニウム塩プロドラッグ
|
ITMI20100260A1
(it)
|
2010-02-19 |
2011-08-20 |
Giulio Scigliano |
Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
|
JP5615899B2
(ja)
|
2010-02-24 |
2014-10-29 |
久光製薬株式会社 |
経皮吸収製剤
|
WO2011105486A1
(ja)
|
2010-02-24 |
2011-09-01 |
久光製薬株式会社 |
貼付剤
|
WO2011107855A2
(en)
|
2010-03-04 |
2011-09-09 |
Torrent Pharmaceuticals Limited |
Sustained release oral liquid suspension dosage form
|
WO2011120044A1
(en)
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
CN102858372A
(zh)
*
|
2010-04-28 |
2013-01-02 |
久光制药株式会社 |
皮肤刺激抑制剂和经皮吸收制剂
|
WO2011143755A1
(en)
|
2010-05-21 |
2011-11-24 |
Serdar Dursun |
Compositions and methods of treating schizophrenia
|
CN101851242B
(zh)
|
2010-05-25 |
2013-07-24 |
上海皓元生物医药科技有限公司 |
阿塞那平中间体的制备方法
|
US8779161B2
(en)
|
2010-06-18 |
2014-07-15 |
Dr. Reddy's Laboratories Limited |
Asenapine maleate
|
EP2598496B1
(en)
|
2010-07-29 |
2014-03-19 |
Laboratorios Lesvi, S.L. |
Novel process for the preparation of asenapine
|
WO2012037457A1
(en)
|
2010-09-16 |
2012-03-22 |
Cornell University |
Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
|
WO2012038975A2
(en)
|
2010-09-22 |
2012-03-29 |
Msn Laboratories Limited |
Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
|
EP2621898A4
(en)
|
2010-09-27 |
2014-01-08 |
Alphora Res Inc |
PROCESS FOR THE PREPARATION OF TETRACYCLIC DERIVATIVES AND INTERMEDIATE PRODUCTS USED IN THE PROCESS
|
WO2012065110A2
(en)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-protected cysteine analogs and related compounds
|
WO2012065102A2
(en)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-t-butyl protected cysteine di-peptide analogs and related compounds
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
CA2815898C
(en)
|
2010-11-17 |
2018-12-18 |
Hexal Ag |
Transdermal therapeutic system comprising buprenorphine
|
WO2012070043A1
(en)
|
2010-11-26 |
2012-05-31 |
Ramot At Tel-Aviv University Ltd. |
Method and composition for weight-gain management
|
CN104523565A
(zh)
|
2010-11-26 |
2015-04-22 |
约翰内斯堡威特沃特斯兰德大学 |
用于治疗精神***症的可植入头颅中的装置
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
AU2011348085B2
(en)
|
2010-12-23 |
2016-12-08 |
Alkermes Pharma Ireland Limited |
Multi- API loading prodrugs
|
EP2468751B1
(en)
|
2010-12-24 |
2016-03-16 |
Medichem, S.A. |
Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012114325A1
(en)
|
2011-02-23 |
2012-08-30 |
Mapi Pharma Limited |
Polymorphs of asenapine maleate
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
US20140037710A1
(en)
|
2011-04-18 |
2014-02-06 |
Hisamitsu Pharmaceutical Co., Inc. |
Method for producing patch, and patch
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524920A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Asenapine Hydrochloride Salt Forms
|
EP2524921A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
EP2524919A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
WO2012156676A1
(en)
|
2011-05-18 |
2012-11-22 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
US9505771B2
(en)
|
2011-05-18 |
2016-11-29 |
Laboratories Lesvi S.L. |
Stable micronised monoclin form of asenapine maleate and its synthesis
|
DE102011076653A1
(de)
|
2011-05-27 |
2012-11-29 |
Acino Ag |
Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
|
KR20130002292A
(ko)
|
2011-06-28 |
2013-01-07 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
AR086798A1
(es)
|
2011-06-29 |
2014-01-22 |
Otsuka Pharma Co Ltd |
Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
US9145421B2
(en)
|
2011-07-20 |
2015-09-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
US9457014B2
(en)
|
2011-07-28 |
2016-10-04 |
Promentis Pharmaceuticals, Inc. |
Cysteine prodrugs
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013040419A1
(en)
|
2011-09-14 |
2013-03-21 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating hyperprolinemia-associated mental disorders
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
JP6149183B2
(ja)
|
2011-10-24 |
2017-06-21 |
ブレイバーン ファーマシューティカルズ,インコーポレイティド |
移植可能チザニジン組成物及びその治療方法
|
WO2013061247A1
(en)
|
2011-10-24 |
2013-05-02 |
Alembic Pharmaceuticals Limited |
Novel process for the preparation of asenapine
|
US20140350081A1
(en)
|
2011-11-04 |
2014-11-27 |
Purdue Research Foundation |
Insect g-coupled receptors useful as targets for insecticides and compounds and reagents identified using the same
|
WO2013080069A1
(en)
|
2011-11-28 |
2013-06-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013114400A2
(en)
|
2012-01-20 |
2013-08-08 |
Rubicon Research Private Limited |
Compressed pharmaceutical compositions of atypical antipsychotics
|
CN103254201B
(zh)
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
RS56226B1
(sr)
|
2012-03-14 |
2017-11-30 |
Levicept Ltd |
P75ntr neurotrofin vezujući protein za terapijsku primenu
|
DE102012205493A1
(de)
|
2012-04-03 |
2013-10-10 |
Acino Ag |
Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
|
WO2013158939A1
(en)
|
2012-04-18 |
2013-10-24 |
Hemoshear, Llc |
In vitro model for pathological or physiologic conditions
|
KR20130120648A
(ko)
|
2012-04-26 |
2013-11-05 |
에스에프씨 주식회사 |
벤조사이클로플루오렌계 화합물 및 이를 포함하는 유기전계발광소자
|
US20150141274A1
(en)
|
2012-05-09 |
2015-05-21 |
The Rockefeller University |
Methods and Compositions for Activity Dependent Transcriptome Profiling
|
WO2013190481A1
(en)
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
KR102013476B1
(ko)
*
|
2012-07-26 |
2019-08-22 |
히사미쓰 세이야꾸 가부시키가이샤 |
첩부제 및 그 제조 방법
|
US8986677B2
(en)
|
2012-07-30 |
2015-03-24 |
Pop Test Cortisol Llc |
Therapeutic compositions and methods
|
WO2014052837A1
(en)
|
2012-09-28 |
2014-04-03 |
Delpor, Inc. |
Device and methods for sustained release of antipsychotic medications
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
JOP20210047A1
(ar)
|
2012-10-25 |
2017-06-16 |
Otsuka Pharma Co Ltd |
عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
|
WO2014078377A1
(en)
|
2012-11-14 |
2014-05-22 |
Agenebio, Inc. |
Methods and compositions for treating schizophrenia
|
JP6440625B2
(ja)
*
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神***病を処置するための方法および組成物
|
CN104812394B
(zh)
|
2012-11-26 |
2018-10-19 |
开普敦大学 |
吩噻嗪衍生物及其治疗肺结核的用途
|
JP2014105205A
(ja)
|
2012-11-30 |
2014-06-09 |
Medical Front Co Ltd |
医用貼付剤
|
US9597291B2
(en)
|
2012-12-11 |
2017-03-21 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Orally disintegrating tablet containing asenapine
|
US9868707B2
(en)
|
2012-12-20 |
2018-01-16 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
TWI646091B
(zh)
|
2012-12-28 |
2019-01-01 |
日商衛斯克慧特股份有限公司 |
鹽類及晶形
|
CN103893139B
(zh)
|
2012-12-28 |
2018-06-08 |
石药集团中奇制药技术(石家庄)有限公司 |
一种阿塞那平组合物及其制备方法
|
AU2013370297A1
(en)
|
2012-12-28 |
2015-07-16 |
Noven Pharmaceuticals, Inc. |
Multi-polymer compositions for transdermal drug delivery
|
CN103965206A
(zh)
|
2013-01-29 |
2014-08-06 |
北京京卫燕康药物研究所有限公司 |
一种阿色纳品马来酸盐的新晶型及制备方法
|
US10154856B2
(en)
|
2013-02-06 |
2018-12-18 |
Mark SILLENDER |
Therapeutic substance transfer catheter and method
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
WO2014165136A1
(en)
|
2013-03-12 |
2014-10-09 |
Antares Pharma, Inc. |
Constant volume prefilled syringes and kits thereof
|
US20140271923A1
(en)
|
2013-03-14 |
2014-09-18 |
Christopher Brian Reid |
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
|
US20160022571A1
(en)
|
2013-03-14 |
2016-01-28 |
Braeburn Pharmaceuticals Bvba Sprl |
Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
|
WO2014160167A1
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
|
WO2014152965A2
(en)
|
2013-03-14 |
2014-09-25 |
The Children's Hospital Of Philadelphia |
Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
|
WO2014160026A2
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
|
US20140276479A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery system with overlay
|
AR095259A1
(es)
|
2013-03-15 |
2015-09-30 |
Noven Pharma |
Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
|
RU2015143438A
(ru)
|
2013-03-15 |
2017-04-21 |
АЛС МАУНТИН ЭлЭлСи |
Фармацевтическая композиция, содержащая активатор амрк и серотонинергическое средство, и способы ее применения
|
US20140274764A1
(en)
|
2013-03-15 |
2014-09-18 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
AU2014232758A1
(en)
|
2013-03-15 |
2015-10-08 |
Ameritox, Ltd. |
Methods of normalizing measured drug concentrations and testing for potential non-compliance with a drug treatment regimen
|
CN105263488A
(zh)
*
|
2013-03-15 |
2016-01-20 |
纳尔制药有限公司 |
含卡巴拉汀的经皮给药***
|
JP6129632B2
(ja)
|
2013-04-24 |
2017-05-17 |
帝國製薬株式会社 |
貼付剤
|
EP3106153A1
(en)
*
|
2013-06-04 |
2016-12-21 |
LTS LOHMANN Therapie-Systeme AG |
Transdermal delivery system
|
JP2016520653A
(ja)
|
2013-06-05 |
2016-07-14 |
シンクロニューロン インコーポレイテッド |
アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
|
IN2013MU02206A
(es)
|
2013-06-28 |
2015-06-12 |
Alembic Pharmaceuticals Ltd |
|
WO2015027342A1
(en)
|
2013-08-30 |
2015-03-05 |
Mcmaster University |
Microgel compositions for delivery of substances to the brain
|
CN104447771A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
一种稳定的马来酸阿塞那平化合物
|
CN104447770A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
阿塞那平化合物
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
US9757330B2
(en)
|
2013-10-18 |
2017-09-12 |
Industrial Technology Research Institute |
Recipe for in-situ gel, and implant, drug delivery system formed thereby
|
WO2015071831A1
(en)
|
2013-11-18 |
2015-05-21 |
Piramal Enterprises Limited |
An improved process for minimising the formation of dehalogenated byproducts
|
WO2015085004A1
(en)
|
2013-12-03 |
2015-06-11 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
EP3076951B1
(en)
|
2013-12-05 |
2020-09-30 |
Celal Albayrak |
Process for the production of drug formulations for oral administration
|
KR20160096155A
(ko)
*
|
2013-12-12 |
2016-08-12 |
히사미쓰 세이야꾸 가부시키가이샤 |
커버재가 부착된 첩부제 및 커버재가 부착된 첩부제 키트
|
CN103772401A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
CN103772402A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
一种新的阿塞那平马来酸盐粗品精制方法
|
CN103772400A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103760280A
(zh)
|
2014-01-10 |
2014-04-30 |
万特制药(海南)有限公司 |
一种用液相色谱法分离测定阿塞那平中间体有关物质的方法
|
CN113413385A
(zh)
|
2014-02-07 |
2021-09-21 |
纽罗克里生物科学有限公司 |
包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
|
WO2015125152A2
(en)
|
2014-02-18 |
2015-08-27 |
Hetero Research Foundation |
Pharmaceutical compositions of asenapine
|
CN106456662A
(zh)
|
2014-02-24 |
2017-02-22 |
奥利金制药公司 |
口服给药的戊聚糖多硫酸盐的组合物及其使用方法
|
WO2015127558A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating micturition in a patient in need thereof
|
WO2015127556A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating defecation in a patient in need thereof
|
SG11201607137WA
(en)
|
2014-02-28 |
2016-09-29 |
Camh |
Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
|
CN103864802B
(zh)
|
2014-03-31 |
2016-08-17 |
四川科伦药业股份有限公司 |
马来酸阿塞那平的制备方法
|
CN104974167B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
CN104974168B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
EP3125892A4
(en)
|
2014-04-04 |
2017-12-27 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
KR20220054908A
(ko)
|
2014-04-04 |
2022-05-03 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
CN104000800A
(zh)
|
2014-04-28 |
2014-08-27 |
万特制药(海南)有限公司 |
马来酸阿塞那平口腔速溶膜剂及其制备方法
|
JP6895755B2
(ja)
|
2014-05-20 |
2021-06-30 |
エルテーエス ローマン テラピー−ジステーメ アーゲー |
経皮送達システムにおける活性薬剤の放出を調節するための方法
|
CN106456568B
(zh)
|
2014-05-20 |
2020-03-27 |
Lts勒曼治疗***股份公司 |
包含界面调节剂的经皮递送***
|
WO2015187289A1
(en)
|
2014-06-03 |
2015-12-10 |
Pop Test Abuse Deterrent Technology Llc |
Drug device configured for wireless communication
|
WO2015191554A1
(en)
|
2014-06-09 |
2015-12-17 |
Intra-Cellular Therapies, Inc. |
Compounds and methods of use to treat schizophrenia
|
CN104133010B
(zh)
|
2014-07-01 |
2019-11-29 |
北京万全德众医药生物技术有限公司 |
高效液相色谱法分离分析阿西马朵林中间体及光学异构体
|
CN104133012B
(zh)
|
2014-07-02 |
2020-01-07 |
北京万全德众医药生物技术有限公司 |
一种高效液相色谱法测定马来酸阿塞那平消旋体的方法
|
US10238648B2
(en)
*
|
2014-07-18 |
2019-03-26 |
Buzzz Pharmaceuticals Ltd. |
Abuse deterrent opioid/opioid-antagonist transdermal patch
|
CN104098580B
(zh)
|
2014-07-22 |
2016-04-13 |
成都百裕科技制药有限公司 |
一种阿塞那平关键中间体的制备方法
|
AU2015296807A1
(en)
|
2014-07-31 |
2017-03-09 |
Noven Pharmaceuticals, Inc. |
Silicone-containing acrylic polymers for transdermal drug delivery compositions
|
ES2562684B1
(es)
|
2014-08-04 |
2017-02-06 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de monitorización de tratamiento antipsicótico
|
WO2016023658A1
(en)
|
2014-08-14 |
2016-02-18 |
Alrise Biosystems Gmbh |
Injectable formulations of asenapine
|
JP2016056142A
(ja)
|
2014-09-11 |
2016-04-21 |
第一三共株式会社 |
Pde10a阻害薬と抗精神病薬の組み合わせ
|
CN104297366A
(zh)
|
2014-09-24 |
2015-01-21 |
万特制药(海南)有限公司 |
马来酸阿塞那平及其杂质的液相分析方法
|
EA201790693A1
(ru)
|
2014-10-14 |
2017-09-29 |
Скюлпт Б.В. |
Коррекция фигуры
|
AU2015335391B2
(en)
|
2014-10-24 |
2018-06-21 |
Launx Biomedical Co., Ltd. |
Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
|
EP3020782B1
(en)
|
2014-11-11 |
2018-08-01 |
SFC Co., Ltd. |
An electroluminescent compound and an electroluminescent device comprising the same
|
AU2015353413A1
(en)
|
2014-11-25 |
2017-05-11 |
Nanocopoeia, Llc |
Amorphous nanoparticles prepared by electrospraying
|
CA2969425A1
(en)
|
2014-12-01 |
2016-06-09 |
The Feinstein Institute For Medical Research |
Use of striatal connectivity patterns for evaluating antipsychotic agents
|
AU2015358343A1
(en)
|
2014-12-05 |
2017-06-01 |
Myriad Genetics, Inc. |
Biomarkers for distinguishing mood disorders
|
EP3031458A1
(en)
|
2014-12-09 |
2016-06-15 |
Iproteos S.L. |
Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
|
US9656441B2
(en)
*
|
2015-01-08 |
2017-05-23 |
Alfred E. Tiefenbacher ( Gmbh & Co. Kg) |
Transdermal patch
|
WO2016114655A1
(en)
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
WO2016121805A1
(ja)
|
2015-01-30 |
2016-08-04 |
積水メディカル株式会社 |
貼付剤
|
BR112017018297B1
(pt)
|
2015-02-25 |
2023-12-05 |
The Regents Of The University Of California |
Uso de um agonista de receptor 5ht selecionado a partir de trazodona e lorcarserina, ou um sal farmaceuticamente aceitável dos mesmos, e uso de um agonista de receptor 5ht selecionado a partir de clemizol, um análogo de clemizol ou um sal farmaceuticamente aceitável dos mesmos
|
US10369116B2
(en)
*
|
2015-03-02 |
2019-08-06 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch comprising an adhesive layer having a nonfunctional silicone oil
|
KR20160107610A
(ko)
|
2015-03-04 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
ITUB20150635A1
(it)
|
2015-04-14 |
2016-10-14 |
Giuseppe Lotito |
Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20190055603A1
(en)
|
2015-04-28 |
2019-02-21 |
Proove Biosciences, Inc. |
System and method for processing genotype information relating to drug metabolism
|
ES2598248B1
(es)
|
2015-06-26 |
2017-12-18 |
Centro De Investigación Biomédica En Red |
Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes antipsicóticos por parte de pacientes que han sufrido un primer episodio psicótico
|
CN107847487B
(zh)
*
|
2015-07-27 |
2021-11-02 |
久光制药株式会社 |
含有阿塞那平的贴剂
|
CN112843023A
(zh)
|
2015-07-27 |
2021-05-28 |
久光制药株式会社 |
含有阿塞那平的贴剂的制造方法
|
CN105566336A
(zh)
|
2016-01-08 |
2016-05-11 |
万特制药(海南)有限公司 |
一种制备阿塞那平去甲基杂质的新方法
|
CN105693735A
(zh)
|
2016-01-15 |
2016-06-22 |
万特制药(海南)有限公司 |
马来酸阿塞那平一种制备方法
|
WO2017131034A1
(ja)
|
2016-01-28 |
2017-08-03 |
久光製薬株式会社 |
経皮吸収製剤
|
JP6658201B2
(ja)
|
2016-03-28 |
2020-03-04 |
東洋インキScホールディングス株式会社 |
貼付剤
|
KR20160108258A
(ko)
|
2016-06-20 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
US20180028461A1
(en)
|
2016-07-27 |
2018-02-01 |
Corium International, Inc. |
Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
|
MX2019007391A
(es)
|
2016-12-20 |
2019-08-16 |
Lts Lohmann Therapie Systeme Ag |
Sistema terapeutico transdermico que contiene asenapina.
|